Evidence map›Paper›PMID 32774253›Full record

ArticleCase reports in oncology

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront.

Husam N Al-Dubai, Mohammed A Yassin, Mohammed A Abdulla, Mahmood S Aldapt, Rola S Ghassoub

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Husam N Al-DubaiInternal Medicine Department, Hamad General Hospital, HMC, Doha, Qatar.
Mohammed A YassinDepartment of Medical Oncology/National Centre for Cancer Care and Research, HMC, Doha, Qatar.
Mohammed A AbdullaDepartment of Medical Oncology/National Centre for Cancer Care and Research, HMC, Doha, Qatar.
Mahmood S AldaptDepartment of Medical Oncology/National Centre for Cancer Care and Research, HMC, Doha, Qatar.
Rola S GhassoubDepartment of Pharmacy, National Centre for Cancer Care and Research, HMC, Doha, Qatar.
National Center for Cancer Care and Research · QAHamad General Hospital · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm classically described as triphasic disease: chronic, accelerated, and blast crisis. There are many unmet needs and unanswered questions about CML. Intermittent fasting in patients with CML on tyrosine kinase inhibitors is among these unmet needs. Here we report the effect of intermittent fasting on response to nilotinib as upfront in a 49-year-old female Muslim who fasted during Ramadan and took her medication once instead of twice daily and remained in major molecular response.

Indexed as

Chronic myeloid leukemiaFastingNilotinibRamadan

Identifiers

PMID32774253
PMCPMC7383202
OpenAlexW3035467370

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.